Jan

2009

Anaphore, Inc.: Series A $25M

Posted in I - Series A, Q - 1Q09, R - WEST, X - Atrimer, X - Immunology, X - Oncology, XX - CA

Anaphore (La Jolla, CA) is developing a class of protein therapeutics, Atrimers, to address immune-mediated disease and oncology, closed a $25M Series A financing. Participants include Apposite Capital, 5am Ventures and Versant Ventures.

Dec

2008

Argos Therapeutics, Inc.: Series C $35.2M

Posted in I - Series C, Q - 4Q08, R - SOUTH EAST, X - HIV, X - Immunology, X - Oncology

Argos Therapeutics (Research Triangle Park, NC) clinical-stage developer of personalized immunotherapies for cancer and HIV, closed a $35.2M Series C financing. Participants include TVM Capital, Mizuho Capital, Morningside Group, Japan Asia Investment Group, Lumira Capital, Forbion Capital Partners, CDP Capital, Intersouth Partners, Aurora Capital and GeneChem.

Dec

2008

Telormedix, SA: Series A $19M

Posted in I - Series A, Q - 3Q08, R - INTERNATIONAL, X - Immunology, X - Oncology

Telormedix (Switzerland) developer of immunotherapeutics for cancer, closed a $19M Series A financing. Participants include Aravis Ventures, Proquest Investments, BSI SA, Nextech Venture and Generali Insurance Group.

Dec

2008

Trillium Therapeutics, Inc.: Series C $12M

Posted in I - Series C, Q - 3Q08, R - INTERNATIONAL, X - Immunology

Trillium Therapeutics (Canada) early-stage company focused on the development of therapies for the treatment of immune-mediated disorders, closed a $12M Series C financing. Participants include VenGrowth Private Equity Partners, BDC Capital and Canadian Medical Discoveries Fund.

Dec

2008

MacroGenics, Inc: Series D $25M

Posted in I - Series D, Q - 3Q08, R - MID ATLANTIC, X - Antibody, X - Immunology, X - Oncology

MacroGenics (Rockland, Maryland) early-stage developer of immunotherapeutics for autoimmune disease, cancer and infectious diseases, closed a $25M Series D financing. Participants include Nextech Venture, Arcus Ventures, Innovis Investments, Lilly Ventures, Alta Partners, CIDC, InterWest Partners, Mitsubishi UFJ, OrbiMed Advisors, Red Abbey Venture Partners, RiverVest, Texas Pacific Group Ventures and Ventures West.

Dec

2008

Nuon Therapeutics, Inc.: Series B $27M

Posted in I - Series B, Q - 3Q08, R - WEST, X - Immunology, X - Inflammation, X - Pain

Nuon Therapeutics (San Mateo, CA) clinical-stage biotechnology company developing therapeutics for autoimmune disease, inflammation and pain, closed a $27M Series B financing. Participants include Frazier Healthcare Ventures, Domain Associates, and GBS Venture Partners.

Nov

2008

Inimex Pharmaceuticals, Inc.: Series B $22M

Posted in I - Series B, Q - 2Q08, R - INTERNATIONAL, X - Immunology

Inimex Pharmaceuticals (Canada) developer of medicines that use selective modulation of the innate immune response, closed a $22M Series B financing. Participants include Morningside Venture Investments, Astellas Venture Management, Advantage Life Science Fund, BC Advantage Funds, BDC Capital, British Columbia Discovery Fund, Canadian Medical Discovery Fund and Working Opportunity Fund.

Nov

2008

Immune Design, Inc.: Series A $18M

Posted in I - Series A, Q - 2Q08, R - NORTH WEST, X - Adjuvant, X - Immunology, X - Vaccines

Immune Design (Seattle, WA) vaccine developer focused on regulating immune responses by targeting dendritic cell biology with combinations of proprietary vectors and adjuvants, closed a $18M Series A financing. Participants include Alta Partners, The Column Group and Versant Ventures.

Nov

2008

Tolera Therapeutics, Inc. Series A $8M

Posted in I - Series B, Q - 2Q08, R - MID WEST, X - Immunology, X - Oncology, X - Rheumatology, X - Transplant

Tolera Therapeutics (Cleveland, OH) focused on immunotherapeutics for transplantation, oncology and autoimmune disease, closed an $8M Series A financing. Participants include Triathlon Medical Ventures, Southwest Michigan First Life Science Fund and Hopen Therapeutics.

Nov

2008

Isconova, AB: Series A $5M

Posted in I - Series A, Q - 2Q08, R - INTERNATIONAL, X - Adjuvant, X - Immunology, X - Vaccines

Isconova (Sweden) developer of antigen delivery system and adjuvant platform, closed a $5M Series A financing. Participants include Innovations Kapital.

Feb

2008

Circassia, Ltd.: Series B $21.8M

Posted in I - Series B, Q - 1Q08, R - INTERNATIONAL, X - Immunology

Circassia (England) a specialty company focused on controlling immune system responses closed a $21.8M Series B financing. Participants include Goldman Sachs, Invesco Perpetual, Imperial Innovations and Lansdowne Partners.

Next Entries »

to top of page...